Document is current
Any future updates will be listed below
-
Authors
Roemer, Frank W. https://orcid.org/0000-0001-9238-7350
Kast, Stephanie
Kemmler, Wolfgang
Collins, Jamie E.
Engelke, Klaus
Guermazi, Ali
Uder, Michael
von Stengel, Simon
-
Funding
Funding for this research was provided by:
Else Kröner-Fresenius-Stiftung (2021_EKSE.22)
Universitätsklinikum Erlangen
- License Information
-
More Information
Article History
Received: 2 July 2025
Revised: 2 July 2025
Accepted: 8 July 2025
First Online: 22 July 2025
Declarations
:
: The EMSOAT (Whole-Body Electromyostimulation for the Treatment of knee OA) study is a multi-center parallel-group (1:1 allocation) superiority randomized controlled trial (RCT) conducted at the Institute of Medical Physics (IMP), Friedrich-Alexander University of Erlangen-Nurnberg (FAU), and the Department of Radiology, University Hospital Erlangen Germany. The RCT was approved by the FAU ethics committee (Nr. 352_20 B) and all participants provided written informed consent prior to enrolment. The project fully complies with the Helsinki Declaration and was prospectively registered at clinicaltrials.gov, NCT05672264, on 05/01/2023.
: FWR is shareholder of Boston Imaging Core Lab (BICL), LLC. and is consultant to Grünenthal GmbH. JEC is consultant to Boston Imaging Core Lab (BICL),LLC. AG has received consultancies, speaking fees, and/or honoraria from Galapagos, Pfizer/Lilly, Roche, AstraZeneca, Merck Serono, and TissuGene and is President and shareholder of Boston Imaging Core Lab (BICL), LLC a company providing image assessment services.
